been identified as a cause of autosomal dominant cerebellar ataxia.⁶ Immunohistochemical studies on cerebellar tissue from an affected member of a family with PKC γ missense mutation showed reduced staining for both PKC γ and ataxin 1 in Purkinje cells, suggesting that there may be a common pathway for PKC γ and polyglutamine-related neurodegeneration.⁶ This hypothesis is also supported by the fact that in spinocerebellar ataxia type 1 (SCA1) transgenic mice, PKC γ degradation occurs before the onset of ataxia, suggesting that the loss of this protein is important for the Purkinje cell dysfunction observed in SCA1 patients.⁵ A link between paraneoplastic and genetic cerebellar ataxia is also illustrated by voltage-gated calcium channel antibodies (VGCC-Ab). VGCC-Ab, especially those directed against the P/Q type VGCC, are mainly associated with Lambert-Eaton myasthenic syndromes (LEMS),⁷ which are paraneoplastic in >70% of the patients. Studies have shown that the frequency of cerebellar ataxia in patients with LEMS is higher than that expected by chance, and that LEMS with ataxia is usually associated with cancer.⁸ VGCC-Ab against the P/Q type have also been found in patients with small cell lung cancer and PCA without LEMS,⁹ suggesting that VGCC

could be associated with some cases of PCA. P/Q type VGCCs are highly expressed in the cerebellum, and gene mutations coding for VGCCs have been identified as a cause of autosomal dominant cerebellar ataxia (SCA6).¹⁰ These data showed that PKC γ and P/Q type VGCCs could be associated with cerebellar ataxia as both paraneoplastic antigen and key mutated protein. From these observations, we can draw two conclusions: although PCA-associated antibodies have not definitively been proven to be pathogenic, they can be used as diagnosis markers to classify subtypes of cerebellar ataxia; although some paraneoplastic antibodies can be observed in only one or two patients, identification of the antigens may have important implications in the identification of key proteins, which could be associated with the neuronal injury of patients with sporadic or genetic cerebellar ataxia.

J Neurol Neurosurg Psychiatry 2006;**77**:1299–1300.

doi: 10.1136/jnnp.2006.100594

Correspondence to: Professor J Honnorat, Neurologie B, Hôpital Neurologique Pierre Wertheimer, 59 Boulevard Pinel, 69677 Bron Cedex, France; jerome.honnorat@chu-lyon.fr

Competing interests: None declared.

REFERENCES

- 1 Graus F, Delattre JY, Antoine JC, *et al*. Recommended diagnostic criteria for paraneoplastic neurological syndromes. *J Neurol Neurosurg Psychiatry* 2004;**75**:1135–40.
- 2 Younes-Mhenni S, Janier MF, Cinotti L, *et al*. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. *Brain* 2004;**127**:2331–8.
- 3 Honnorat J, Cartalat-Carel S. Advances in paraneoplastic neurological syndromes. *Curr Opin Oncol* 2004;**16**:614–20.
- 4 Sabater L, Batailler L, Carpentier A F, *et al*. Protein kinase C gamma autoimmunity in paraneoplastic cerebellar degeneration and non-small cell lung cancer. *J Neurol Neurosurg Psychiatry* 2006;**77**:1359–62.
- 5 Skinner PJ, Vierra-Green CA, Clark HB, *et al*. Altered trafficking of membrane proteins in Purkinje cells of SCA1 transgenic mice. *Am J Pathol* 2001;**159**:905–13.
- 6 Chen DH, Brkanac Z, Verlinde CLWJ, *et al*. Missense mutations in the regulatory domain of PKC: a new mechanism for dominant nonepisodic cerebellar ataxia. *Am J Hum Genet* 2003;**72**:839–49.
- 7 Motomura M, Lang B, Johnston I, *et al*. Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. *J Neurol Sci* 1997;**147**:35–42.
- 8 Clouston PD, Saper CB, Arbizu T, *et al*. Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome. *Neurology* 1992;**42**:1944–50.
- 9 Mason WP, Graus F, Lang B, *et al*. Paraneoplastic cerebellar degeneration and small cell lung cancer. *Brain* 1997;**120**:1279–300.
- 10 Restituito S, Thompson RM, Eliet J, *et al*. The polyglutamine expansion in spinocerebellar ataxia type 6 causes a beta subunit-specific enhanced activation of P/Q-type calcium channels in *Xenopus* oocytes. *J Neurosci* 2000;**20**:6394–403.

Prevention of delayed cerebral ischaemia

Prevention of delayed cerebral ischaemia after subarachnoid haemorrhage

R Al-Shahi, M Robson

Physiological abnormalities are a worthwhile target

Delayed cerebral ischaemia (DCI) affects more than one quarter of patients between 3 and 14 days after the onset of their aneurysmal subarachnoid haemorrhage, and accounts for about one third of patients who are dead or dependent as a result of the haemorrhage. Despite the importance of DCI, little can be done to prevent it: only calcium antagonists are supported by good evidence, and the effectiveness of nimodipine is modest (20 patients need to be treated to prevent one poor outcome).¹ Future hope is offered only by the window of

opportunity between subarachnoid haemorrhage and DCI onset, and sufficient clinical research interest in finding further interventions for the prophylaxis and treatment of DCI.

In trying to discover whether potentially modifiable physiological abnormalities are a worthwhile target for intervention to prevent DCI, the paper by Naidech *et al*² (p 1340) explores the association between cerebral infarcts on computed tomograms of the brain after aneurysmal subarachnoid haemorrhage and a physiological derangement score at the time of admission to hospital

(based on a patient's oxygenation, acidosis, glycaemic control and blood pressure). In contrast with the study that originally derived the physiological derangement score,³ the present study is small and retrospective, with an over-representation of subarachnoid haemorrhages that were severe or located in the posterior circulation. Furthermore, the study used a radiological marker of DCI rather than clinically important outcome data after discharge from hospital. The authors strove to identify cerebral infarcts due to vasospasm, but multivariate analysis found only clinical severity of subarachnoid haemorrhage and physiological derangement score to be associated with cerebral infarcts. However, the size of the study sample precluded the inclusion of other known determinants of DCI (such as prolonged duration of unconsciousness at onset of subarachnoid haemorrhage) and its design did not allow an analysis of the influence of endovascular or surgical treatment.

The study by Naidech *et al*² provokes many questions. Might alternative scoring systems using additional variables be better at predicting poor clinical outcome?⁴ Might altered physiology

simply be an epiphenomenon reflecting subarachnoid haemorrhage severity? Could physiological derangement at later stages of admission to hospital be even more influential (as is the case for hypomagnesaemia⁵)? As vasospasm is neither necessary nor sufficient to account for DCI, retaining the focus on determinants of poor outcome and DCI is likely to be most beneficial for patients. There are many potential targets for prevention of DCI, including endothelial activation, cortical spreading depression, excitotoxicity mediated by raised intracellular calcium, apoptosis, nitric oxide depletion, free radical formation and mitochondrial dysfunction, many of which may be influenced by the physiological abnormalities in the patient.

For now, the correction of some physiological abnormalities (such as hypoxia, hypotension and hyperglycaemia) after aneurysmal subarachnoid haemorrhage seems to be clinical common sense, not least to try and mitigate

the major effect on cardiorespiratory function after subarachnoid haemorrhage⁴. This approach further reinforces the importance of multidisciplinary team management, including critical care.⁶ To investigate whether DCI could be prevented by more aggressive treatment of physiological derangements would require large randomised controlled trials, in addition to the ongoing clinical trials of magnesium, simvastatin and clazosentan.⁴

J Neurol Neurosurg Psychiatry 2006;**77**:1300–1301.

doi: 10.1136/jnnp.2006.100958

.....

Authors' affiliations

R Al-Shahi, M Robson, Department of Clinical Neurosciences, University of Edinburgh, Western General Hospital, Edinburgh, UK

Correspondence to: R Al-Shahi, Department of Clinical Neurosciences, University of

Edinburgh, Western General Hospital, Edinburgh EH4 2XU, UK; Rustam.Al-Shahi@ed.ac.uk

Competing interests: None declared.

REFERENCES

- 1 Rinkel GJE, Feigin VL, Algra A, *et al.* Calcium antagonists for aneurysmal subarachnoid haemorrhage. *Cochrane Database Syst Rev* 2005; Issue 1, CD000277.
- 2 Naidech AM, Drescher J, Tamul P, *et al.* Acute physiological derangement is associated with early radiographic cerebral infarction after subarachnoid haemorrhage. *J Neurol Neurosurg Psychiatry* 2006;**77**:1340–4.
- 3 Claassen J, Vu A, Kreiter KT, *et al.* Effect of acute physiologic derangements on outcome after subarachnoid hemorrhage. *Crit Care Med* 2004;**32**:832–8.
- 4 Schuiling WJ, de Weerd AW, Dennesen PW, *et al.* The simplified acute physiology score to predict outcome in patients with subarachnoid haemorrhage. *Neurosurgery* 2005;**57**:230–6.
- 5 van den Bergh WM, Algra A, van der Sprenkel JW, *et al.* Hypomagnesaemia after aneurysmal subarachnoid hemorrhage. *Neurosurgery* 2003;**52**:276–81.
- 6 Al-Shahi R, White P M, Davenport R J, *et al.* Subarachnoid haemorrhage. *BMJ* 2006;**333**:235–40.

BNF for Children 2006, second annual edition

In a single resource:

- guidance on drug management of common childhood conditions
- hands-on information on prescribing, monitoring and administering medicines to children
- comprehensive guidance covering neonates to adolescents

For more information please go to bnfc.org